NCT07691944Not yet recruiting
Effect of VExUS Score on Postoperative Pulmonary Complications in Elderly Patients
Effect of VExUS Score-Guided Intraoperative Goal-Directed Fluid Therapy on Postoperative Pulmonary Complications in Elderly Patients Undergoing McKeown Minimally Invasive Esophagectomy: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 9 Jul 2026
Brief summary (registry, in English)
Brief Summary This clinical trial aims to evaluate whether perioperative goal-directed fluid therapy (GDFT) targeting a venous excess ultrasound (VExUS) score of 1 can reduce postoperative pulmonary complications (PPCs) in elderly patients undergoing McKeown minimally invasive esophagectomy (MIE). The study will also assess postoperative organ microcirculatory perfusion and quality of recovery. Key research questions the trial seeks to answer include: Does VExUS score-guided GDFT reduce the incidence of PPCs in elderly patients following McKeown MIE? Do participants receiving VExUS-guided GDFT achieve better clinical outcomes? Investigators will compare VExUS score-targeted GDFT with fluid therapy guided by the standard Vigileo-FloTrac™ system, to determine if the VExUS-guided approach reduces the occurrence of postoperative pulmonary complications in elderly patients. Participant assessments and data collection include: VExUS score assessment at four time points: preoperatively, after thoracic phase of surgery, after abdominal phase of surgery, and at the end of surgery. Concomitant measurements will include capillary refill time (CRT, in minutes), perfusion index (PI), blood lactate level (Lac, in mmol/L), and central venous oxygen saturation (ScvO₂, in percent). Postoperative lung ultrasound score assessment. Recording of clinical outcomes including length of intensive care unit (ICU) stay (in days), postoperative hospital length of stay (in days), 30-day postoperative readmission rate due to pulmonary complications (in percent), and in-hospital postoperative mortality rate (in percent).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 126 (estimated)
- First submitted
- 18 Jun 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- First Affiliated Hospital of Chongqing Medical University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07691944
What you commit to
- Study type: Observational
- Planned participants: 126
- From 1 Aug 2026 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Respiratory failure (SaO₂ \< 60 mmHg and/or PaCO₂ \> 50 mmHg)
- Severe cardiac dysfunction (NYHA class III-IV)
- Angina pectoris within the past 3 months or acute myocardial infarction (STEMI/NSTEMI) within the past 6 months
- Pulmonary hypertension (pulmonary artery systolic pressure, PASP \> 35 mmHg)
- Cognitive impairment (Mini-Mental State Examination, MMSE \< 27) and inability to cooperate with follow-up
Lab values
- Chronic kidney disease (CKD stage ≥ 3a) (estimated glomerular filtration rate, eGFR \< 45 mL/min/1.73 m²)
Other
- Moderate to severe tricuspid stenosis/regurgitation (valve orifice area \< 1.5 cm² / vena contracta width ≥ 0.3 cm)
- Decompensated cirrhosis (Child-Pugh class ≥ B)
Who the study is looking for
- Age between 65 and 80 years old
- Scheduled for elective McKeown MIE
- ASA physical status classification I to III
- Body mass index (BMI) between 18 kg/m² and 30 kg/m² (exclusive of 18 kg/m²)
Age in the registry: 65 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.